HER2 Support Group Forums - View Single Post - Well

schoonder · 08-20-2009, 04:32 PM

Irene,
I’m not sure if Genentech as yet is totally aware on best method of administering this experimental drug. Company very recently received a patent on T-DM1 that defines this invention and includes possible methods of use.
Below enclosed two excerpts from this patent discuss possibility of starting treatment with toxin loaded antibody, and after some period of time, a follow up with a naked (unconjugated) antibody. With NED, this might become a good maintenance treatment. Here are those excerpts:
“In a preferred embodiment, the treatment is initiated with an anti-ErbB antibody-maytansinoid conjugate, followed by maintenance treatment with an unconjugated or `naked` anti-ErbB antibody. This strategy may eliminate or reduce tumor cells resistant to the naked antibody in the initial round because of the ability of the antibody-DM1 conjugate to effectively kill such tumor cells.”

“In a preferred embodiment, the patients are treated initially with anti-ErbB-maytansinoid conjugate followed by therapy with unconjugated anti-ErbB antibody. Preferably, the anti-ErbB antibody in the conjugate and the unconjugated antibody are the same antibody. For example, treatment could be initiated with weekly injections of HERCEPTIN.RTM.-DM1 at about 0.5-5 mg/kg, preferably at about 1-3 mg/kg for 4-6 weeks, with the option of repeating this treatment. Patients can then be rolled over to conventional HERCEPTIN.RTM. therapy, which typically consists of treatment with a 4 mg/kg initial dose of HERCEPTIN.RTM., followed by weekly treatment with a maintenance dose of 2 mg/kg. However, the 4 mg/kg initial dose may be omitted, with therapy going straight to the 2 mg/kg maintenance dose.”
http://patft.uspto.gov/netacgi/nph-P...&RS=PN/7575748
Hope this gives you more insight into this candidate drug that has been so effective for you.

08-20-2009, 04:32 PM	#7
schoonder Senior Member Join Date: Jul 2008 Posts: 186	Re: Well - i am off of tdm1 Irene, I’m not sure if Genentech as yet is totally aware on best method of administering this experimental drug. Company very recently received a patent on T-DM1 that defines this invention and includes possible methods of use. Below enclosed two excerpts from this patent discuss possibility of starting treatment with toxin loaded antibody, and after some period of time, a follow up with a naked (unconjugated) antibody. With NED, this might become a good maintenance treatment. Here are those excerpts: “In a preferred embodiment, the treatment is initiated with an anti-ErbB antibody-maytansinoid conjugate, followed by maintenance treatment with an unconjugated or `naked` anti-ErbB antibody. This strategy may eliminate or reduce tumor cells resistant to the naked antibody in the initial round because of the ability of the antibody-DM1 conjugate to effectively kill such tumor cells.” “In a preferred embodiment, the patients are treated initially with anti-ErbB-maytansinoid conjugate followed by therapy with unconjugated anti-ErbB antibody. Preferably, the anti-ErbB antibody in the conjugate and the unconjugated antibody are the same antibody. For example, treatment could be initiated with weekly injections of HERCEPTIN.RTM.-DM1 at about 0.5-5 mg/kg, preferably at about 1-3 mg/kg for 4-6 weeks, with the option of repeating this treatment. Patients can then be rolled over to conventional HERCEPTIN.RTM. therapy, which typically consists of treatment with a 4 mg/kg initial dose of HERCEPTIN.RTM., followed by weekly treatment with a maintenance dose of 2 mg/kg. However, the 4 mg/kg initial dose may be omitted, with therapy going straight to the 2 mg/kg maintenance dose.” http://patft.uspto.gov/netacgi/nph-P...&RS=PN/7575748 Hope this gives you more insight into this candidate drug that has been so effective for you.